US 8,502,018 Β· Granted 2013-08-06
Methods of modifying eukaryotic cells
A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
Patent details
- Publication number
- US 8,502,018
- Filing date
- 2011-06-20
- Grant date
- 2013-08-06
- Assignee
- Regeneron Pharmaceuticals, Inc.
- Inventor(s)
- MURPHY ANDREW J., YANCOPOULOS GEORGE D.
- CPC class
- C12P21/00
Want to file your own patent?
Run your idea through our free scanner β weβll show you which existing patents are conceptually closest, including this one if itβs a match.
Free patentability scanRelated patents in this cluster
- US 5,633,425: Transgenic non-human animals capable of producing heterologous antibodies
- US 5,545,807: Production of antibodies from transgenic animals
- US 5,661,016: Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
- US 6,075,181: Human antibodies derived from immunized xenomice